GO-013

N/A

Report date: 2025/08/05 15:34:02

Base Information

Drug NameGO-013
Drug Alias NameGO-013LCB22A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A